Program
Anti-CCR8 Monoclonal Antibody HC006
Its studies are led by HC Biopharma.
Furthest: phase 1, since Mar 5, 20242 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HC Biopharma | 22 open or running | phase 1since Mar 5, 2024 | Mar 5, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 5, 2024First study: phase 1 study in Advanced Solid TumorFirst studyNCT06304571 · 76 planned · China
- Apr 30, 2025Phase 1 study in Advanced CancerNCT06963814 · 252 planned · China
TargetBeta
CCR8 →read by rule
“A monoclonal antibody directed against human C-C motif chemokine receptor 8 (CCR8), ”NCIt, by rule
Other programs on CCR8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cafelkibart | Sino Biopharmaceutical | phase 3 | 7 |
| CCR8 Inhibitor IPG7236rule | nanjing-immunophage-biotech-co-ltd | phase 2 | 3 |
| denikitugrule | Gilead Sciences | phase 2 | 3 |
| imzokitug | Bristol-Myers Squibb | phase 2 | 2 |
| Anti-CCR8 Antibody-drug Conjugate TAK-188rule | Takeda | phase 2 | 1 |
| azirkitug | AbbVie | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06963814Advanced Cancer · China | 1 | Recruiting | May 30, 2026 | 252 |
| NCT06304571Advanced Solid Tumor · China | 1 | Recruiting | Mar 15, 2026 | 76 |
How it is read
Names in the registry
- “HC006”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.